UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Elevated cytokines and chemokines in peripheral blood of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma

PLoS pathogens, 2021-10, Vol.17 (10), p.e1010025-e1010025

2021

Volltextzugriff (PDF)

Prevalence of non-Hodgkin lymphoma patients at high-risk of failure after CAR T-cell therapy eligible for bridging radiation therapy

Frontiers in oncology, 2024-08, Vol.14, p.1425506

2024

Volltextzugriff (PDF)

Phase 1b Dose‐finding Study of Venetoclax With Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B‐cell Lymphoma

HemaSphere, 2022-06, Vol.6 (6), p.e719-n/a

2022

Volltextzugriff (PDF)

Reduced‐dose fludarabine, cyclophosphamide, and rituximab (FCR‐Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia

American journal of hematology, 2015-06, Vol.90 (6), p.487-492

2015

Volltextzugriff (PDF)

Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma

JCI insight, 2021-03, Vol.6 (6)

2021

Volltextzugriff (PDF)

P-209 The Influence of the Gut Microbiome on Myeloma Progression

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S158-S158

2024

Volltextzugriff (PDF)

Gut Microbiota Diversity and Composition Is Associated with High-Risk Myeloma

Blood, 2023-11, Vol.142 (Supplement 1), p.3294-3294

2023

Volltextzugriff (PDF)

Elevated cytokines and chemokines in peripheral blood of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma

PLoS pathogens, 2021-10, Vol.17 (10)

2021

Volltextzugriff (PDF)

Post-ASCT consolidation with elotuzumab, lenalidomide, and dexamethasone or elotuzumab, pomalidomide, and dexamethasone in high-risk and ultra-high-risk multiple myeloma: a retrospective single-center study

Leukemia & lymphoma, 2024-07, p.1-9

2024

Volltextzugriff (PDF)

A Phase 1/2 Study of Carfilzomib, Iberdomide and Dexamethasone (KID) in Patients with Newly Diagnosed Transplant-Eligible Multiple Myeloma

Blood, 2023-11, Vol.142 (Supplement 1), p.2022-2022

2023

Volltextzugriff (PDF)

A Phase 2b Study of Selinexor in Combination with Carfilzomib, Daratumumab, or Pomalidomide in Patients with Multiple Myeloma Relapsing on Current Therapy

Blood, 2023-11, Vol.142 (Supplement 1), p.6714-6714

2023

Volltextzugriff (PDF)

A phase I/II study of carfilzomib, iberdomide (CC-220), and dexamethasone (KID) in patients with newly diagnosed transplant-eligible multiple myeloma

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e20043-e20043

2023

Volltextzugriff (PDF)

A phase IIb study of selinexor in combination with carfilzomib, daratumumab, or pomalidomide in patients with multiple myeloma relapsing on current therapy

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e20042-e20042

2023

Volltextzugriff (PDF)

Gut Microbiome Composition Is Associated with Engraftment Syndrome in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Blood, 2022-11, Vol.140 (Supplement 1), p.4843-4844

2022

Volltextzugriff (PDF)

Phase 1b dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in patients with relapsed/refractory mantle cell lymphoma

Leukemia & lymphoma, 2023-12, Vol.64 (14), p.2225-2235

2023

Volltextzugriff (PDF)

Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high‐risk multiple myeloma

American journal of hematology, 2021-11, Vol.96 (11), p.E430-E433

2021

Volltextzugriff (PDF)

A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone As Post Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Multiple Myeloma

Blood, 2017-12, Vol.130, p.1831-1831

2017

Volltextzugriff (PDF)

Phase Ib-II Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib, w/ Lenalidomide and Rituximab in Relapsed / Refractory Mantle Cell Lymphoma

Blood, 2017-12, Vol.130, p.2785-2785

2017

Volltextzugriff (PDF)

Venous Assessment Prior to Mobilization Significantly Reduced Use of Apheresis Central Venous Catheters

Blood, 2016-12, Vol.128 (22), p.5735-5735

2016

Volltextzugriff (PDF)

Safety and Efficacy of Consolidation Therapy with Ipilimumab Plus Nivolumab after Autologous Stem Cell Transplantation

Transplantation and cellular therapy, 2021-05, Vol.27 (5), p.391-403

2021

Volltextzugriff (PDF)

A Phase II Study of the Combination of FCR-Lite and Lenalidomide Followed By Lenalidomide Maintenance in Front-Line CLL: The FCR2 Regimen

Blood, 2014-12, Vol.124 (21), p.4678-4678

2014

Volltextzugriff (PDF)

1 – 23 von 23

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(23)

Sprache

Englisch
(23)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Elevated cytokines and chemokines in peripheral blood of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma

Prevalence of non-Hodgkin lymphoma patients at high-risk of failure after CAR T-cell therapy eligible for bridging radiation therapy

Phase 1b Dose‐finding Study of Venetoclax With Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B‐cell Lymphoma

Reduced‐dose fludarabine, cyclophosphamide, and rituximab (FCR‐Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia

Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma

P-209 The Influence of the Gut Microbiome on Myeloma Progression

Gut Microbiota Diversity and Composition Is Associated with High-Risk Myeloma

Elevated cytokines and chemokines in peripheral blood of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma

Post-ASCT consolidation with elotuzumab, lenalidomide, and dexamethasone or elotuzumab, pomalidomide, and dexamethasone in high-risk and ultra-high-risk multiple myeloma: a retrospective single-center study

A Phase 1/2 Study of Carfilzomib, Iberdomide and Dexamethasone (KID) in Patients with Newly Diagnosed Transplant-Eligible Multiple Myeloma

A Phase 2b Study of Selinexor in Combination with Carfilzomib, Daratumumab, or Pomalidomide in Patients with Multiple Myeloma Relapsing on Current Therapy

A phase I/II study of carfilzomib, iberdomide (CC-220), and dexamethasone (KID) in patients with newly diagnosed transplant-eligible multiple myeloma

A phase IIb study of selinexor in combination with carfilzomib, daratumumab, or pomalidomide in patients with multiple myeloma relapsing on current therapy

Gut Microbiome Composition Is Associated with Engraftment Syndrome in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Phase 1b dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in patients with relapsed/refractory mantle cell lymphoma

Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high‐risk multiple myeloma

A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone As Post Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Multiple Myeloma

Phase Ib-II Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib, w/ Lenalidomide and Rituximab in Relapsed / Refractory Mantle Cell Lymphoma

Influence of the Gut Microbiome on Clinical Outcomes in the CPIT-001 Trial, a Phase Ib-IIA Study of Combined Checkpoint Inhibition with Nivolumab and Ipilimumab after Autologous Hematopoietic Stem Cell Transplantation in Patients at High-Risk for Post-Transplant Recurrence

Preliminary Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (I) and Nivolumab (N) As Consolidation Following Autologous Stem Cell Transplantation (ASCT) for High-Risk Hematologic Malignancies - Cpit-001 Trial

Venous Assessment Prior to Mobilization Significantly Reduced Use of Apheresis Central Venous Catheters

Safety and Efficacy of Consolidation Therapy with Ipilimumab Plus Nivolumab after Autologous Stem Cell Transplantation

A Phase II Study of the Combination of FCR-Lite and Lenalidomide Followed By Lenalidomide Maintenance in Front-Line CLL: The FCR2 Regimen

Suchergebnisse filtern